Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices. The ...

Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, Home ...

Eli Lilly is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans, and reducing prices for certain dosages. The ...

The pharmaceutical company said it has launched 7.5 and 10 milligram single-dose vials of its Zepbound drug, also known as tirzepatide, which join the existing lineup of 2.5 and 5 milligram vials.

MarketWatch was able to verify Zeng's claims via videos and was also able to order delivery of Ozempic to an address in China. The price was 798 yuan ($108) for a one-month supply that is injected ...

Self-pay patients with obesity also have additional vial options, including at 2.5 mg, 5 mg, 7.5 mg, and 10 mg doses. Lilly is also slashing the price for a month's supply of the two lowest doses by ...

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...

New 7.5 mg and 10 mg Zepbound single-dose vials now available for $499 per month via Zepbound Self Pay Journey Program 2.5 mg and 5 mg vial prices reduced INDIANAPOLIS ...

Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...

Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...

Eli Lilly has reduced the price of its weight-loss drug Zepbound, offering higher doses in vials at a discount to boost demand and compete with Novo Nordisk's Wegovy. The price adjustment aims to ease ...